UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | January 5, 2005 |
L.A.M. Pharmaceutical, Corp.
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 000-30641 | 52-2278236 |
| _____________________ (State or other jurisdiction | _____________ (Commission | ______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 800 Sheppard Avenue West, Commercial Unit 1, Toronto, Ontario | M3H 6B4 | |
| _________________________________ (Address of principal executive offices) | ___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 416-633-7047 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On January 11, 2005, L.A.M. Pharmaceutical, Corp. (the "Company") announced that it entered into a provisional agreement, dated January 5, 2005, with Finest Enterprises Limited and China Elegant Development Limited to acquire New World Kellerton, a pharmaceutical company based in Xinyang, China. A copy of the provisional agreement is attached hereto as Exhibit 8.1 and is incorporated herein by reference as if restated in full.
The Company accounced the execution of the provisional agreement in a press release dated January 11, 2005, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference as if restated in full.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
8.1 Provisional Agreement between L.A.M. Pharmaceutical, Corp. and Finest
Enterprises Limited.
99.1 L.A.M. Pharmaceutical, Corp. Press Release dated January 11,2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| L.A.M. Pharmaceutical, Corp. | ||||
| January 11, 2005 | By: | Joseph T. Slechta | ||
| Name: Joseph T. Slechta | ||||
| Title: President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer and Director | ||||
Exhibit Index
| Exhibit No. | Description | |
8.1 | Provisional Agreement between L.A.M. Pharmaceutical, Corp. and Finest Enterprises Limited | |
99.1 | L.A.M. Pharmaceutical, Corp. Press Release dated January 11, 2005 |